The 'Dispatched' Podcast
BioPharmaDispatch - discussing the issues impacting the Australian biopharmaceutical and life sciences sectors with Paul Cross and Felicity McNeill.
The 'Dispatched' Podcast
Latest Episodes
The 'Dispatched' Week in Review Podcast - 6 November
A call for greater accountability in institutional decision-making processes that too often ignore realities and patient needs. Spending priorities delay and deny access to medicines. Term limits for advisory committees can lead to renewal and ...
The 'Dispatched' Week in Review Podcast - 26 October
A newly released document has, for the first time, revealed forecast net spending on the PBS to the end of the decade after rebates, and it's not good news. Why are officials calling it a new 'charging' framework instead of cost recovery? The d...
The 'Dispatched' Podcast - Series 5. Ep.36
Welcome to the first podcast video recording. Recorded at the recent Pfizer Invites event, this episode focuses on the rapidly emerging private market and whether it can catalyse meaningful medicines reform to benefit patients who are either wa...
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
Should industry groups present the agreement negotiations to patient groups and 'invited' stakeholders, and if so, what should they say? Why the private market for GLP-1 medicines could be a historic catalyst for the changes so many want.
The 'Dispatched' Podcast Week in Review - Series 5. Ep.34
The impact of new media guidance from Australia's health technology regulator can now be assessed against the backdrop of its use of an AI platform initially developed for, and still used by, intelligence and law enforcement agencies. Why is th...